Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.

Prompt treatment improves survival; however, reference standard enzyme-linked immunosorbent assay and FRETS-VWF73 ADAMTS13 activity assays have long turnaround times (TATs) that necessitate empiric treatment of many patients who ultimately are found not to have TTP.

及时治疗可以提高生存率；然而，参考标准的酶联免疫吸附测定和FRETS-VWF73 ADAMTS13活性测定的周转时间（TATs）较长，这导致许多最终被证实并非TTP的患者不得不接受经验性治疗。

Rapid assays with analytical TATs <1 hour have recently become available.

最近，分析周转时间（TAT）小于1小时的快速检测方法已经变得可行。

We conducted a systematic reviewand meta-analysisof the performance characteristics of rapid assays relative to reference standard assays for ADAMTS13 activity for patients with suspected or confirmed TTP.

我们对疑似或确诊为血栓性血小板减少性紫癜（TTP）患者的ADAMTS13活性快速检测方法相对于参考标准检测方法的性能特征进行了系统评价和荟萃分析。

Nineteen studies representing 3 rapid ADAMTS13 assays and 4207 patient samples were included.

纳入了代表3种快速ADAMTS13检测和4207个患者样本的19项研究。

The HemosIL AcuStar chemiluminescence immunoassay (CLIA) demonstrated high sensitivity (0.98; 95% confidence interval[CI], 0.94-1.00), specificity (0.99; 95% CI, 0.97-1.00), and positive (PPV) (0.96; 95% CI, 0.90-0.98) and negative predictive values (NPV) (0.99; 95% CI, 0.99-1.00).

HemosIL AcuStar化学发光免疫分析法（CLIA）显示出高敏感性（0.98；95%置信区间[CI]，0.94-1.00）、特异性（0.99；95% CI，0.97-1.00）以及阳性预测值（PPV）（0.96；95% CI，0.90-0.98）和阴性预测值（NPV）（0.99；95% CI，0.99-1.00）。

The Technofluor fluorescence resonance energy transfer (FRET) and Technoscreen assays had sensitivity of 0.93 (95% CI, 0.86-0.96) and 0.98 (95% CI, 0.42-1.00), specificity of 0.98 (95% CI, 0.95-0.99) and 0.87 (95% CI, 0.76-0.94), PPV of 0.97 (95% CI, 0.85-1.00) and 0.71 (95% CI, 0.59-0.80), and NPV of 0.96 (95% CI, 0.93-0.98) and 0.99 (95% CI, 0.72-1.00), respectively.

Technofluor荧光共振能量转移(FRET)和Technoscreen检测的敏感性分别为0.93（95%置信区间，0.86-0.96）和0.98（95%置信区间，0.42-1.00），特异性分别为0.98（95%置信区间，0.95-0.99）和0.87（95%置信区间，0.76-0.94），阳性预测值(PPV)分别为0.97（95%置信区间，0.85-1.00）和0.71（95%置信区间，0.59-0.80），阴性预测值(NPV)分别为0.96（95%置信区间，0.93-0.98）和0.99（95%置信区间，0.72-1.00）。

The proportion of discrepant results (relative to reference standard assays) was 0.04 (95% CI, 0.03-0.05) for HemosIL AcuStar, 0.04 (95% CI, 0.02-0.06) for Technofluor FRET, and 0.11 (95% CI, 0.07-0.16) for the Technoscreen assay.

与参考标准检测相比，HemosIL AcuStar的不一致结果比例为0.04（95%置信区间，0.03-0.05），Technofluor FRET为0.04（95%置信区间，0.02-0.06），Technoscreen检测为0.11（95%置信区间，0.07-0.16）。

With rapid TAT and high sensitivity, the HemosIL AcuStar CLIA seems able to reliably avert empiric plasma exchange, corticosteroids, and caplacizumab in patients without TTP.

凭借快速的周转时间（TAT）和高灵敏度，HemosIL AcuStar CLIA似乎能够可靠地避免在没有血栓性血小板减少性紫癜（TTP）的患者中使用经验性血浆置换、皮质类固醇和卡普拉西珠单抗。